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Abstract
Background: Cetuximab is a commonly used antibody agent in the treatment of colorectal or head and
neck cancer. Although it is generally well tolerated in most patients, cetuximab has been associated with
some rare but serious adverse events. Aseptic meningitis is one such distinctly uncommon adverse drug
reaction.
Case presentation: We present the case of a middle-aged Caucasian patient, who presented with fever
and headache within a few hours of starting cetuximab therapy and was diagnosed with cetuximab-induced aseptic
meningitis after a complete workup.
Conclusion: To our knowledge, this is the ninth case of cetuximab-induced aseptic meningitis reported
in literature. Because of a nonspecific clinical presentation, this adverse drug reaction can be easily
misdiagnosed. It is important to increase awareness of this potentially severe reaction among oncologists.
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Background
Cetuximab, a human/mouse chimeric monoclonal
antibody against the epidermal growth factor recep-
tor (EGFR), is used as a single agent and in combin-
ation with chemotherapy or radiation therapy in
metastatic colorectal cancer and locally advanced or
metastatic head and neck squamous cell cancer. In
cetuximab Summary of Product Characteristics
(SPC), aseptic meningitis is mentioned as a rare ner-
vous system disorder but with an unknown fre-
quency. Rare but serious cancer drug-associated
adverse reactions can be identified in the postmar-
keting experience after large numbers of patients
have been exposed to the drug. As a rare complica-
tion, we report a case of aseptic meningitis associ-
ated with the first intravenous (I.V.) administration
of cetuximab.
Case presentation
A 66-year-old woman, with a WHO performance sta-
tus of 0, history of chronic smoking, high blood
pressure and atrial fibrillation, was diagnosed with a
stage IVa locally advanced laryngeal squamous-cell
carcinoma (cT3N2M0). She had neither history of
headache nor previous allergic drug reactions. She
received neoadjuvant chemotherapy by docetaxel, cis-
platin and fluorouracil, with a marked tumor regres-
sion following three courses. She was then offered
definitive external beam radiotherapy with concurrent
weekly cetuximab. On her first cycle, she received
routine premedication with dexchlorpheniramine
5 mg I.V. followed by a loading dose of 400 mg/m2
cetuximab I.V. over 2 h (5 mg/min) without develop-
ing any infusion reaction. Her usual medicines were
rilmenidine, pantoprazole, fenofibrate, and acetamino-
phen. However, 4 h after completing cetuximab infu-
sion, she was admitted to hospital with sudden
headaches, photophobia, neck stiffness and vomiting
without fever.
Cerebrospinal fluid (CSF) analysis showed a cloudy
liquid with elevated protein (1.5 g/L; normal range:
0.2–0.4 g/L), a red blood cell count of 6/μL, and a
leukocyte count of 4100/μL (normal range: 0–4/μL),
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90 % of them were neutrophils, 9 % were lympho-
cytes, and 1 % were monocytes. The glucose level in
CSF was 3.16 mM (normal range: 2.7–4.2 mM) with
a glucose level in blood of 7.3 mM (ratio 0.43). The
white blood cell count was 7900/μL with 7000/μL
neutrophils, and a C-reactive protein at 5.9 mg/L
(normal range <6.0 mg/L). The patient was treated
with empiric antibiotic therapy (ceftriaxone I.V.) for
7 days without corticosteroids and recovered neuro-
logically within 8 days. Bacterial cultures remained
negative. Viral analysis including a viral encephalitis
panel was performed by polymerase chain reaction
and remained negative. Repeat CSF analysis was ini-
tially planned 8 days after admission to the hospital
but the lumbar puncture failed and was not repeated
as the patient was well.
Symptoms resolution was reported by day 2. Radi-
ation therapy was started 3 weeks after for 8 weeks
and cetuximab was reintroduced 28 days after with a
lower dose of 250 mg/m2. Methylprednisolone 80 mg
I.V. was added to dexchlorpheniramine 5 mg I.V.
and the infusion flow rate of cetuximab was de-
creased to 2 mg/min. She tolerated it well and no
side effects were reported all along the other add-
itional infusions up to 10 weeks. At a follow-up of
18 months the patient is well with no evidence of
tumor recurrence.
Discussion
The temporal association, clinical and laboratory
findings strongly support the diagnosis of cetuximab-
induced aseptic meningitis. As for our patient, most
patients with aseptic meningitis are treated with an-
tibiotics, pending identification of infectious agent
and recover within 2 weeks, without any long-term
neurological sequelae.
Distinction on clinical grounds alone is not possible,
and the CSF pattern with neutrophilic pleocytosis
may cause confusion with infectious meningitis. Reso-
lution occurs several days after drug discontinuation.
Diagnosis of aseptic meningitis is based on viral and
bacterial CSF profiles remaining sterile.
Nonsteroidal anti-inflammatory drugs, antibiotics,
intravenous immunoglobulins, antiepileptic drugs, and
monoclonal antibodies (mainly tumor necrosis factor
inhibitors) are the most frequent cause of drug-
induced meningitis. History of drug intake is crucial
because there are no specific characteristics associated
with a specific drug [1].
In order to try to understand the pathophysiology
of aseptic meningitis due to cetuximab, we can draw
similarities with aseptic meningitis occurring with
I.V. immunoglobulin (IVIG) infusion [2–6]. The fac-
tors, which may predispose to the development of
the meningitis, include fast infusion rates and a
history of headaches. The symptoms of aseptic men-
ingitis generally occur within 24 h of starting treat-
ment. Theories of aseptic meningitis with IVIG have
included an allergic hypersensitivity reaction or
serum immunoglobulin crossing the blood brain bar-
rier. Hence, this entry of serum immunoglobulin into
the cerebrospinal fluid would be responsible for the
inflammatory reaction. It has also been suggested
that releasing histamine, serotonin, and prostaglan-
dins could affect the meningeal microvasculature,
such as in migraine mechanism [7].
The first occurrence of drug-induced aseptic men-
ingitis related to cetuximab was reported in 2000 by
Baselga et al. in a phase I clinical trial [8]. Since
then, 7 other cases of cetuximab-induced aseptic
meningitis have been described. Cetuximab was
reintroduced successfully for three of them with an
appropriate premedication and a slower infusion
rate, one patient had a positive rechallenge without
corticosteroid premedication [9, 10]. Characteristics
of the reported patients from the literature were
compiled recently [11] and are now completed with
a new one [12] and our present report in Table 1.
Note that these adverse reactions always occurred
during the first administration which may suggest a
dose-related response, even though an idiosyncratic
response in patients with risk factors is also pos-
sible. Surprisingly, there are no cases described in
colorectal cancer whereas cetuximab is commonly
being dosed at 500 mg/m2 (higher dose) every
2 weeks for a larger number of patients.
Conclusions
Cetuximab-induced aseptic meningitis should be
known as a potential severe adverse drug reaction
with corticosteroids introduced before loading dose
and slowed infusion. This has been taken into ac-
count in the 2014 SPC renewal, as « Prior to the
first infusion, patients must receive premedication
with an antihistamine and a corticosteroid at least
1 h prior to administration of cetuximab. This pre-
medication is recommended prior to all subsequent
infusions » and « The initial dose should be given
slowly and speed of infusion must not exceed 5 mg/
min (1 ml/min). For the subsequent doses, the infu-
sion rate must not exceed 10 mg/min (2 ml/min) ».
This report added to the others may serve as a
reference for health practitioners managing cetuxi-
mab. Rechallenge with cetuximab after complete
neurological resolution is feasible and should be
attempted, especially when cetuximab is given in a
curative intent.
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Table 1 Characteristics of the described cases of cetuximab-induced aseptic meningitis
Case, Date Age range Indication for
cetuximab
Cetuximab dose
(duration),
premedication
Symptoms (time onset),
imaging
Initial CSF analysis Follow-up CSF
analysis
Treatment, recovery Rechallenge
1, 2000 [8] N/R N/R 100 mg/m2 N/R N/A N/A N/R N/R
2, 2009 [10] 40–49 Recurrent laryngeal
squamous cell
carcinoma
400 mg/m2 (first
administration 2 h),
diphenhydramine
50 mg IV
Frontal headache, 38.9 °C
fever (few hours after
infusion), N/R
2300/μl with 98 %
neutrophils, protein
1.04 g/L, normal
glucose level,
negative cultures
“Resolution of
neutrophilic
pleocytosis”,
normal protein
levels (day 4)
Empirical antibiotic
treatment, acyclovir,
recovery N/R
Negative rechallenge after 1
week (250 mg/m2, premedication:
dexamethasone, diphenhydramine)
without adverse events
3, 2009 [10] 40–49 Locally advanced
squamous cell
carcinoma of right
tonsil
400 mg/m2 (first
administration 2 h),
diphenhydramine
50 mg IV
Severe frontal headache,
39.4 °C fever, neck
stiffness, photophobia
(about 8 h after infusion),
N/R
2267/μl with 90 %
neutrophils, protein
1.46 g/L, normal
glucose level,
negative cultures
“No white blood
cells”, elevated
but improved
protein (0.69 g/L)
Empirical antibiotic
treatment, acyclovir,
dexamethasone,
recovery from
meningeal
symptoms after
12 days
Negative rechallenge after 2 weeks
(250 mg/m2, premedication:
dexamethasone, diphenhydramine,
famotidine) without adverse events
4, 2010 [13] 70–79 NSCLC (stage IIIA) 400 mg/m2 (first
administration,
duration N/R), N/R
Severe headache, nausea,
vomiting, neck stiffness
(few hours after infusion),
brain CT scan normal
528/μl with 87 %
neutrophils, “
modestly elevated
protein”, normal
glucose level
N/A Empirical antibiotic
treatment (stopped
after infection was
ruled out), recovery
without neurological
sequelae
N/R
5, 2010 [13] 50–59 Metastatic NSCLC 400 mg/m2 (first
administration,
duration N/R), N/R
Acute encephalopathy
(few hours after infusion),
brain CT scan and MRI
normal
cell count and
fraction of
neutrophils N/A,
protein 1.16 g/L,
glucose 2.8
mmol/L, negative
cultures
N/A Empirical antibiotic
treatment (stopped
after infection was
ruled out), recovery
within several days
N/R
6, 2012 [9] 50–59 Squamous maxillary
cancer (stage IVb)
400 mg/m2 (first
administration),
diphenhydramine
50 mg IV
Frontal headache, neck
discomfort, 39.9 °C fever
(few hours after infusion),
brain CT scan normal
1025/μl with 92 %
neutrophils, protein
1.65 g/L, normal
glucose level,
negative bacterial
culture, PCR (HSV)
negative
N/A Empirical antibiotic
treatment, resolution
of symptoms – no
complications.
Positive rechallenge after 4 weeks
(250 mg/m2), recurrent CSF
pleiocytosis (715/μl, 93 %
neutrophils), protein 1.22 g/L,
premedication: diphenhydramine.
Rechallenge three and following
without adverse events.
7, 2015 [11] 60–69 Recurrent advanced
oropharyngeal
squamous cell
carcinoma
400 mg/m2 (first
administration,
2 h), clemastine
2 mg oral
Headache, mutism,
hypertension, neck
stiffness, 39.2 °C fever
(about 9 h after infusion),
brain CT scan and MRI
non-diagnostic
1413/μl with 92 %
neutrophils, protein
1.79 g/L, normal
glucose level 3.5
mmol/L, negative
cultures and
serologies
Cell count 1/μl,
protein 0.68 g/L,
normal glucose
level 4.0 mmol/L
Empirical antibiotic
treatment,
dexamethasone
(stopped after
infection was ruled
out), myoclonic
jerks and NCSE
after 3 days, recovery
within 14 days
The patient refused
rechallenge.
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Table 1 Characteristics of the described cases of cetuximab-induced aseptic meningitis (Continued)
8, 2015 [12] 50–59 Tonsillar squamous
cell cancer
400 mg/m2 (first
administration)
Frontal headache (10/10
in severity), fever (1 h
after infusion), brain CT
scan
473/μl with 80 %
neutrophils in tube
1 and 500/μl with
62 % neutrophilsin
tube 4.
150 and 50 cells/μL
red blood cells,
protein 1,28 g/L,
normal glucose level
N/A Empirical antibiotic
treatment for 4 days
(stopped after
infection was ruled
out). Symptomatic
improvement after
2 days and recovery
within 4 days
Negative rechallenge after 7 days,
the patient received a second
dose of cetuximab at 250 mg/m2
without adverse events.
9, 2015
Present case
60–69 Locally advanced
laryngeal squamous
cell carcinoma
400 mg/m2 (first
administration, 2 h),
dexchlorpheniramine
5 mg IV
Headache, photophobia,
neck stiffness, vomiting,
nausea (few hours after
infusion), N/A
Leukocytes count
4100/μL with 90 %
of neutrophils, 6/μL
red blood cells,
protein 1.5 g/L,
normal glucose
level in 3.16 mmol/L.,
negative viral and
bacterial cultures.
N/A Empirical antibiotic
treatment for 7 days,
recovery without
sequelae within
several days
Negative rechallenge after 28
days (250 mg/m2, premedication:
methylprednisolone,
dexchlorpheniramine)
without adverse events.
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